Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
190
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis

V. G. Hallb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;d Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;d Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9353-0059View further author information
ORCID Icon,
C. Lima Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
N. R. Saundersa Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
E. Klimevskia Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
T. H. O. Nguyenc Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, AustraliaView further author information
,
L. Kedzierskic Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, AustraliaView further author information
,
J. F. Seymourb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;d Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0003-2188-6835View further author information
ORCID Icon,
V. Wadhwae Department of Ambulatory Services, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
K. A. Thurskya Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaView further author information
,
M. K. Yonga Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaView further author information
,
K. Kedzierskac Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, AustraliaView further author information
,
M. A. Slavina Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaView further author information
&
B. W. Teha Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaORCID Iconhttps://orcid.org/0000-0003-0213-5470View further author information
ORCID Icon show all
Pages 1600-1604 | Received 05 Nov 2023, Accepted 03 Mar 2023, Published online: 21 Jun 2023

References

  • Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for High-Risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542.
  • Salmanton-García J, Marchesi F, Glenthøj A, et al. Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere. 2022;6(11):e789. doi: 10.1097/HS9.0000000000000789.
  • Wang L, Kaelber DC, Xu R, et al. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931. doi: 10.1016/j.blre.2022.100931.
  • Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022;6(7):2014–2034. doi: 10.1182/bloodadvances.2021006333.
  • Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188–2200. doi: 10.1056/NEJMoa2116620.
  • Therapeutic Goods Administration. TGA provisionally approves AstraZeneca’s combination therapy (tixagevimab and cilgavimab, EVUSHELD) - for pre-exposure prevention (prophylaxis) of COVID-19. 2022. [accessed February 28 2023]. Available from: https://www.tga.gov.au/tga-provisionally-approves-astrazenecas-combination-therapy-tixagevimab-and-cilgavimab-evusheld-pre-exposure-prevention-prophylaxis-covid-19
  • Hoang T, da Silva AG, Jennison AV, et al. AusTrakka: fast-tracking nationalized genomics surveillance in response to the COVID-19 pandemic. Nat Commun. 2022;13(1):865. doi: 10.1038/s41467-022-28529-9.
  • Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033–1036. doi: 10.1038/s41591-020-0913-5.
  • Nguyen THO, Rowntree LC, Petersen J, et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity. 2021;54(5):1066–1082.e5. doi: 10.1016/j.immuni.2021.04.009.
  • United States Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. [accessed March 01 2023]. Available from: https://www.fda.gov/media/73679/download
  • Stuver R, Shah GL, Korde NS, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40(6):590–591. doi: 10.1016/j.ccell.2022.05.007.
  • Kertes J, David SSB, Engel-Zohar N, et al. Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality. Clin Infect Dis. 2022;76:e126–e132.
  • Ulloa AC, Buchan SA, Daneman N, et al. Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA. 2022;327(13):1286–1288. doi: 10.1001/jama.2022.2274.
  • Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468–470. doi: 10.1056/NEJMc2207519.
  • Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med. 2022;386(15):1475–1477. doi: 10.1056/NEJMc2201933.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.